These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 2140951

  • 1. Differential effects of D1 and D2 dopamine receptor agonists on substantia nigra pars reticulata neurons.
    Waszczak BL.
    Brain Res; 1990 Apr 09; 513(1):125-35. PubMed ID: 2140951
    [Abstract] [Full Text] [Related]

  • 2. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG, Walters JR.
    Brain Res; 1987 Mar 10; 405(2):234-46. PubMed ID: 2952219
    [Abstract] [Full Text] [Related]

  • 3. Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism.
    Abercrombie ED, DeBoer P.
    J Neurosci; 1997 Nov 01; 17(21):8498-505. PubMed ID: 9334422
    [Abstract] [Full Text] [Related]

  • 4. Dopamine D2, receptor-mediated modulation of the GABAergic inhibition of substantia nigra pars reticulata neurons.
    Martin LP, Waszczak BL.
    Brain Res; 1996 Aug 12; 729(2):156-69. PubMed ID: 8876984
    [Abstract] [Full Text] [Related]

  • 5. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX, Walters JR.
    J Pharmacol Exp Ther; 1994 Dec 12; 271(3):1434-43. PubMed ID: 7996456
    [Abstract] [Full Text] [Related]

  • 6. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar 12; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 7. D1 agonist-induced excitation of substantia nigra pars reticulata neurons: mediation by D1 receptors on striatonigral terminals via a pertussis toxin-sensitive coupling pathway.
    Martin LP, Waszczak BL.
    J Neurosci; 1994 Jul 12; 14(7):4494-506. PubMed ID: 7913124
    [Abstract] [Full Text] [Related]

  • 8. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
    Engber TM, Anderson JJ, Boldry RC, Kuo S, Chase TN.
    Neuroscience; 1993 Jun 12; 54(4):1051-61. PubMed ID: 8101981
    [Abstract] [Full Text] [Related]

  • 9. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
    Huang KX, Bergstrom DA, Ruskin DN, Walters JR.
    Synapse; 1998 Sep 12; 30(1):18-29. PubMed ID: 9704877
    [Abstract] [Full Text] [Related]

  • 10. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH, Starr MS.
    Neuroscience; 1987 Dec 12; 23(3):1001-10. PubMed ID: 2963970
    [Abstract] [Full Text] [Related]

  • 11. Neurophysiological investigation of effects of the D-1 agonist SKF 38393 on tonic activity of substantia nigra dopamine neurons.
    Carlson JH, Bergstrom DA, Weick BG, Walters JR.
    Synapse; 1987 Dec 12; 1(5):411-6. PubMed ID: 2975067
    [Abstract] [Full Text] [Related]

  • 12. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons.
    Kelland MD, Freeman AS, Chiodo LA.
    Synapse; 1988 Dec 12; 2(4):416-23. PubMed ID: 2973142
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM, Marin C, Susel Z, Chase TN.
    Eur J Pharmacol; 1993 Jun 04; 236(3):385-93. PubMed ID: 8102970
    [Abstract] [Full Text] [Related]

  • 14. Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393.
    Ruskin DN, Rawji SS, Walters JR.
    J Pharmacol Exp Ther; 1998 Jul 04; 286(1):272-81. PubMed ID: 9655869
    [Abstract] [Full Text] [Related]

  • 15. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
    Subramaniam S, Lucki I, McGonigle P.
    Brain Res; 1992 Feb 07; 571(2):313-22. PubMed ID: 1351781
    [Abstract] [Full Text] [Related]

  • 16. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Feb 07; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 17. Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration.
    Weick BG, Engber TM, Susel Z, Chase TN, Walters JR.
    Brain Res; 1990 Jul 16; 523(1):16-22. PubMed ID: 2119854
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study.
    Hu XT, Wang RY.
    J Neurosci; 1988 Nov 16; 8(11):4340-8. PubMed ID: 2972814
    [Abstract] [Full Text] [Related]

  • 19. Dopamine agonist-mediated rotation in rats with unilateral nigrostriatal lesions is not dependent on net inhibitions of rate in basal ganglia output nuclei.
    Ruskin DN, Bergstrom DA, Mastropietro CW, Twery MJ, Walters JR.
    Neuroscience; 1999 Nov 16; 91(3):935-46. PubMed ID: 10391472
    [Abstract] [Full Text] [Related]

  • 20. Dopaminergic and cholinergic stimulation of the ventrolateral striatum elicit rat jaw movements that are funnelled via distinct efferents.
    Adachi K, Hasegawa M, Fujita S, Sato M, Miwa Y, Ikeda H, Koshikawa N, Cools AR.
    Eur J Pharmacol; 2002 May 03; 442(1-2):81-92. PubMed ID: 12020685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.